Hyupjin, Pharming sales and marketing update

Pharming granted Hyupjin commercialization rights to Ruconest conestat alfa in Korea to treat acute attacks of hereditary angioedema (HAE). Hyupjin will purchase the recombinant human complement 1 (C1) esterase inhibitor from Pharming at an undisclosed fixed transfer price. Terms were not disclosed. ...